Welcome to our dedicated page for Astria Therapeutics SEC filings (Ticker: ATXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astria Therapeutics Inc (ATXS) files regular SEC disclosures that reveal critical information about its clinical-stage drug development programs, financial runway, and operational risks. For biopharmaceutical companies without product revenue, quarterly 10-Q reports and annual 10-K filings provide the most comprehensive view of cash reserves, research spending, and clinical trial timelines that determine whether the company has sufficient capital to complete its development objectives.
Form 8-K filings from Astria frequently announce material events such as clinical trial results, regulatory decisions, licensing agreements, and equity financing transactions. These real-time disclosures often contain detailed data tables and management commentary that explain the clinical significance of trial outcomes, helping investors understand whether results support advancement to the next development phase. For companies pursuing rare disease indications, 8-K filings may include FDA correspondence regarding orphan drug designations or breakthrough therapy status that can accelerate approval pathways.
The company's 10-K annual reports detail research and development expenses across programs, intellectual property portfolios covering therapeutic candidates, and risk factor disclosures that outline the numerous ways drug development can fail. These filings break down spending by development stage, reveal the number of patents protecting each program, and disclose any manufacturing or regulatory challenges that could delay commercialization. Investors analyzing biotech companies use this information to model cash burn rates and estimate when the company may need additional financing.
Form 4 insider transaction reports track when executives and board members buy or sell ATXS shares, providing signals about management confidence in clinical programs. Significant insider purchases sometimes precede positive clinical announcements, while selling patterns may indicate routine compensation liquidation or other factors. Proxy statements (DEF 14A) reveal executive compensation structures, including stock option grants and performance milestones tied to clinical achievements, showing how management incentives align with shareholder interests in advancing therapies toward approval.
Our platform delivers AI-powered summaries of these complex regulatory documents, highlighting key financial metrics, clinical trial updates, and risk factor changes without requiring you to parse hundreds of pages of technical disclosures. Whether you're tracking the company's progress toward Phase 3 trial completion or monitoring its cash position to assess dilution risk, consolidated access to Astria's complete SEC filing history provides the transparency necessary for informed investment decisions in clinical-stage biotechnology.
Astria Therapeutics plans to merge with BioCryst Pharmaceuticals, creating a combined rare‑disease biotech focused on hereditary angioedema (HAE) and other immunologic conditions. Astria stockholders are being asked to approve the Merger Agreement at a special meeting on January 21, 2026. At closing, each share of Astria common stock (other than excluded and dissenting shares) will be converted into 0.59 of a share of BioCryst common stock plus $8.55 in cash, subject to adjustment to keep total new BioCryst shares at or below 19.9% of its pre‑merger shares. Any reduction in the stock portion would be offset by more cash, calculated using a BioCryst share value of $7.54. Based on BioCryst prices of
Astria Therapeutics (ATXS) signed a definitive agreement to be acquired by BioCryst Pharmaceuticals. At closing, each Astria share will be converted into $8.55 in cash plus 0.59 shares of BioCryst common stock, with cash paid in lieu of fractional shares. If issuing BioCryst stock would exceed 19.9% of BioCryst’s pre-close outstanding shares, the share component will be reduced and the cash amount increased to offset the change.
The deal is subject to customary conditions, including Astria stockholder approval, HSR clearance, an effective S‑4, and Nasdaq listing of the BioCryst shares. The companies anticipate closing in Q1 2026, after which Astria will be delisted and become a BioCryst subsidiary. BioCryst obtained a
Astria Therapeutics Schedule 13G/A summary: Four reporting persons—RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah—filed a joint Schedule 13G amendment reporting that they do not beneficially own any shares of Astria Therapeutics common stock. The cover pages show aggregate beneficial ownership of 0 shares, representing 0.0% of the class, and no sole or shared voting or dispositive power is reported. The filing disclaims group status and incorporates a prior joint filing agreement by reference.
Astria Therapeutics, Inc. filed a Form S-8 to register additional securities under its Second Amended and Restated 2015 Stock Incentive Plan (as amended), the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan (as amended). The filing incorporates prior S-8 registrations by reference, attaches plan documents and counsel consents, and is signed by CEO Jill C. Milne and other officers and directors. The registrant is incorporated in Delaware and lists its principal executive offices in Boston, Massachusetts.
Astria Therapeutics reported results from its unaudited Form 10-Q showing $76.3 million in cash and $182.9 million in short-term investments, totaling $259.2 million of available liquidity and an accumulated deficit of $741.6 million. For the six months ended June 30, 2025, the company recorded a net loss of $66.8 million (basic and diluted loss per share $1.15), compared with a $44.1 million loss a year earlier. Total assets were $281.9 million versus $342.4 million at year-end 2024.
Clinical and business developments are centered on navenibart and STAR-0310. Astria initiated the global Phase 3 ALPHA-ORBIT trial for navenibart with topline results expected in early 2027 and continues the long-term ORBIT-EXPANSE program. Prior ALPHA-STAR and ALPHA-SOLAR data showed robust reductions in monthly HAE attack rates (~92% overall) and attack-free rates up to 67% in cohorts, with favorable tolerability reported. Subsequent to period end, Astria licensed navenibart rights in Japan to Kaken for a $16.0 million upfront payment, potential $16.0 million in milestones and tiered royalties (mid-teens to 30%), plus support and cost reimbursement for the Phase 3 program.
R&D spending increased to $53.7 million for the six months, up from $36.4 million, reflecting Phase 3 and STAR-0310 activity. Management estimates current resources, together with the Kaken upfront payment and reimbursements, are expected to fund operations into 2028, but the company states it will need substantial additional funding to complete development and commercialization.
Astria Therapeutics (ATXS) signed an exclusive license with Kaken Pharmaceutical for Japanese rights to navenibart, its long-acting plasma-kallikrein mAb for hereditary angioedema (HAE). Kaken will lead development, regulatory submissions and commercialization in Japan and will support Astria’s ALPHA-ORBIT Phase 3 trial.
Financial terms: Astria receives a $16 million upfront, up to $16 million in commercial/sales milestones, and tiered royalties ranging from the mid-teens to 30 % of net sales. Royalties run until the later of patent or regulatory exclusivity expiry, or 10 years after first sale.
The upfront plus partial Phase 3 cost reimbursements extend Astria’s cash runway into 2028, covering completion of the Phase 3 program for navenibart and the Phase 1a study of STAR-0310. Management cautions that substantial additional funding will still be needed to finish development and commercialization.
The agreement includes a joint steering committee, Kaken’s right of first negotiation for non-HAE indications, and termination rights for breach, insolvency, safety issues or at Kaken’s convenience (90-day notice).
FAQ
What is the current stock price of Astria Therapeutics (ATXS)?
What is the market cap of Astria Therapeutics (ATXS)?
